Newron Pharmaceuticals S.p.A. | Finanzwire

Basculer en Français

8396	Companies
122097	Keywords
60577	Articles
65553	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

BRIEF

published on 12/13/2024 at 07:05, 8 days 12 hours ago

Newron and EA Pharma Sign License Agreement for Evenamide in Asia

Newron Pharmaceuticals Evenamide Schizophrenia Treatment License Agreement EA Pharma
PRESS RELEASE

published on 12/13/2024 at 07:00, 8 days 12 hours ago

Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories
Newron Pharmaceuticals S.p.A. and EA Pharma (a subsidiary of Eisai Co., Ltd.) have signed a license agreement for evenamide in Japan and other Asian territories, aiming to address unmet medical needs in patients with schizophrenia

Schizophrenia Newron Pharmaceuticals Evenamide License Agreement EA Pharma
BRIEF

published on 09/19/2024 at 07:05, 3 months 2 days ago

Newron Pharmaceuticals Presents H1 2024 Results and Business Update

Clinical Trials Newron Pharmaceuticals Evenamide Schizophrenia Treatment H1 2024
PRESS RELEASE

published on 09/19/2024 at 07:00, 3 months 2 days ago

Newron presents H1 2024 results and provides business update
Newron Pharmaceuticals presents H1 2024 financial results and operational highlights, focusing on evenamide studies for schizophrenia treatment and corporate developments

Financial Results Newron Pharmaceuticals Evenamide Schizophrenia Treatment H1 2024
BRIEF

published on 06/25/2024 at 17:50, 5 months 26 days ago

Newron Pharmaceuticals Highlights 2024 Investor Day in NYC

Investor Day Clinical Trials Schizophrenia Newron Pharmaceuticals Evenamide
PRESS RELEASE

published on 06/25/2024 at 17:45, 5 months 26 days ago

Newron Pharmaceuticals reports on its 2024 Investor Day in New York City
Newron Pharmaceuticals reports on its 2024 Investor Day in New York City, highlighting evenamide's potential in treating treatment-resistant schizophrenia. Leading experts present clinical data and benefits of evenamide

Clinical Data Schizophrenia 2024 Investor Day Newron Pharmaceuticals Evenamide
BRIEF

published on 06/18/2024 at 17:50, 6 months 3 days ago

Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City

Investor Day Clinical Research Schizophrenia Newron Pharmaceuticals Evenamide
PRESS RELEASE

published on 06/18/2024 at 17:45, 6 months 3 days ago

Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City. Key opinion leaders to review findings on evenamide program for treatment-resistant schizophrenia

Investor Day Neuroscience Schizophrenia Newron Pharmaceuticals Evenamide
BRIEF

published on 06/05/2024 at 17:50, 6 months 16 days ago

Newron Pharmaceuticals to Host 2024 Investor Day in New York City

Investor Day New York City Schizophrenia Newron Pharmaceuticals Evenamide
PRESS RELEASE

published on 06/05/2024 at 17:45, 6 months 16 days ago

Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City
Newron Pharmaceuticals announces 2024 Investor Day in New York City focusing on evenamide for treatment-resistant schizophrenia. Leading experts to present new findings

Schizophrenia 2024 Investor Day Newron Pharmaceuticals Evenamide Neurobiology

1 2 ... 4

Accesswire

Published on 12/21/2024 at 01:30, 17 hours 49 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 49 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 19 hours 14 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 19 hours 19 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 19 hours 49 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

EQS Group

Published on 12/21/2024 at 00:51, 18 hours 27 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 34 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 1 day ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 1 day ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

ARYZTA AG Announces New Board Technology Committee

Les Echos

Published on 12/21/2024 at 12:17, 7 hours 1 minute ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago

Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 5 hours ago

Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days ago

Share capital decrease by way of treasury shares cancellation

View all LES ECHOS COMFI WIRE